The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 701-711

  Chai, Lilly ^a   McLaren, Rajashree P ^a   Byrne, Ann ^a   Chuang, Wei Lien ^a   Huang, Yinyin ^a   Dufault, Michael R ^a   Pacheco, Joshua ^a   Madhiwalla, Shruti ^a   Zhang, Xiaokui ^a   Zhang, Mindy ^a   Teicher, Beverly A ^a   Carter, Kara ^a   Cheng, Seng H ^a   Leonard, John P ^a   Xiang, Yibin ^a   Vasconcelles, Michael ^a   Goldberg, Mark A ^a   Copeland, Diane P ^a   Klinger, Katherine W ^a   Lillie, James ^a   Madden, Stephen L ^a   Jiang, Yide A ^a   more..

^a GENZYME CORPORATION   (United States)

Author keywords

Chemosensitization; GCS inhibitor; Glucosylceramide synthase; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GENZ 123346; GLYCOPROTEIN P; GLYCOSPHINGOLIPID; MULTIDRUG RESISTANCE PROTEIN 1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL LINE; CHEMOSENSITIVITY; CHEMOSENSITIZATION; DRUG POTENTIATION; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; DIOXANES; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSYLTRANSFERASES; HEP G2 CELLS; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; PYRROLIDINES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 79952028218     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.888     Document Type: Article

References (45)

1. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006. (Pubitemid 43336035)
2. Leonard GD, Fojo T and Bates SE: The role of ABC transporters in clinical practice. Oncologist 8: 411-424, 2003. (Pubitemid 37238869)
3. Lavie Y and Liscovitch M: Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj J 17: 253-259, 2000. (Pubitemid 32055913)
4. Sietsma H, Veldman RJ and Kok JW: The involvement of sphingolipids in multidrug resistance. J Membr Biol 181: 153-162, 2001. (Pubitemid 32548063)
5. Lavie Y, Cao H, Bursten SL, Giuliano AE and Cabot MC: Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 271: 19530-19536, 1996. (Pubitemid 26271630)
6. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL and Cabot MC: Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 18: 475-480, 1998. (Pubitemid 28174859)
7. Wennekes T, van den Berg RJ, Boot RG, van der Marel GA, Overkleeft HS and Aerts JM: Glycosphingolipids-nature, function, and pharmacological modulation. Angew Chem Int Ed Engl 48: 8848-8869, 2009.
8. Modrak DE, Gold DV and Goldenberg DM: Sphingolipid targets in cancer therapy. Mol Cancer Ther 5: 200-208, 2006.
9. Bleicher RJ and Cabot MC: Glucosylceramide synthase and apoptosis. Biochim Biophys Acta 1585: 172-178, 2002. (Pubitemid 36092082)
10. Liu YY, Han TY, Giuliano AE and Cabot MC: Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274: 1140-1146, 1999.
11. Liu YY, Han TY, Giuliano AE, Ichikawa S, Hirabayashi Y and Cabot MC: Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-alpha-induced apoptosis. Exp Cell Res 252: 464-470, 1999. (Pubitemid 29530276)
12. Liu YY, Han TY, Giuliano AE and Cabot MC: Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15: 719-730, 2001. (Pubitemid 32245990)
13. Liu YY, Han TY, Giuliano AE, Hansen N and Cabot MC: Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem 275: 7138-7143, 2000. (Pubitemid 30146262)
14. Regina Todeschini A and Hakomori SI: Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta 1780: 421-433, 2008. (Pubitemid 351381254)
15. Sietsma H, Veldman RJ, Kolk D, et al: 1-phenyl-2-decanoylamino-3- morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin Cancer Res 6: 942-948, 2000. (Pubitemid 30159352)
16. Barbour S, Edidin M, Felding-Habermann B, Taylor-Norton J, Radin NS and Fenderson BA: Glycolipid depletion using a ceramide analogue (PDMP) alters growth, adhesion, and membrane lipid organization in human A431 cells. J Cell Physiol 150: 610-619, 1992.
17. Olshefski RS and Ladisch S: Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int J Cancer 93: 131-138, 2001. (Pubitemid 32539512)
18. Liour SS and Yu RK: Differential effects of three inhibitors of glycosphingolipid biosynthesis on neuronal differentiation of embryonal carcinoma stem cells. Neurochem Res 27: 1507-1512, 2002. (Pubitemid 36014162)
19. Lee L, Abe A and Shayman JA: Improved inhibitors of glucosylceramide synthase. J Biol Chem 274: 14662-14669, 1999.
20. Kok JW, Babia T, Filipeanu CM, Nelemans A, Egea G and Hoekstra D: PDMP blocks brefeldin A-induced retrograde membrane transport from golgi to ER: evidence for involvement of calcium homeostasis and dissociation from sphingolipid metabolism. J Cell Biol 142: 25-38, 1998. (Pubitemid 28341137)
21. Griner RD and Bollag WB: Inhibition of [(3)H]thymidine transport is a nonspecific effect of PDMP in primary cultures of mouse epidermal keratinocytes. J Pharmacol Exp Ther 294: 1219-1224, 2000. (Pubitemid 30666880)
22. Shabbits JA and Mayer LD: P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 1: 205-213, 2002.
23. Lavie Y, Cao H, Volner A, et al: Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272: 1682-1687, 1997. (Pubitemid 27043253)
24. Xie P, Shen YF, Shi YP, et al: Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 32: 475-480, 2008. (Pubitemid 351295915)
25. Norris-Cervetto E, Callaghan R, Platt FM, Dwek RA and Butters TD: Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. J Biol Chem 279: 40412-40418, 2004. (Pubitemid 39287630)
26. Sietsma H, Dijkhuis AJ, Kamps W and Kok JW: Sphingolipids in neuroblastoma: their role in drug resistance mechanisms. Neurochem Res 27: 665-674, 2002.
27. Dijkhuis AJ, Klappe K, Jacobs S, et al: PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy. Mol Cancer Ther 5: 593-601, 2006.
28. McEachern KA, Fung J, Komarnitsky S, et al: A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91: 259-267, 2007. (Pubitemid 46819125)
29. Wennekes T, Meijer AJ, Groen AK, et al: Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J Med Chem 53: 689-698, 2010.
30. Shen DW, Cardarelli C, Hwang J, et al: Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261: 7762-7770, 1986. (Pubitemid 17208699)
31. Boyd MR and Pall KD: Some practical considerations and applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Dev Res 34: 91-109, 1995.
32. Silberstein C, Copeland DP, Chiang W, Repetto HA and Ibarra C: A glucosylceramide synthase inhibitor prevents the cytotoxic effects of shiga toxin-2 on human renal tubular epithelial cells. J Epithelial Biol Pharmacol 1: 71-75, 2008.
33. Liu YY, Yu JY, Yin D, et al: A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J 22: 2541-2551, 2008. (Pubitemid 351948671)
34. Prinetti A, Millimaggi D, D'Ascenzo S, et al: Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem J 395: 311-318, 2006.
35. Szakacs G, Annereau JP, Lababidi S, et al: Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6: 129-137, 2004. (Pubitemid 39485685)
36. Glavinas H, Krajcsi P, Cserepes J and Sarkadi B: The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1: 27-42, 2004.
37. Norris-Cervetto E, Butters TD, Martin C, Modok S, Dwek RA and Callaghan R: Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors? Eur J Pharmacol 530: 195-204, 2006.
38. van Helvoort A, Smith AJ, Sprong H, et al: MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87: 507-517, 1996. (Pubitemid 26374324)
39. van Helvoort A, Giudici ML, Thielemans M and van Meer G: Transport of sphingomyelin to the cell surface is inhibited by brefeldin A and in mitosis, where C6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity. J Cell Sci 110: 75-83, 1997. (Pubitemid 27057946)
40. Lala P, Ito S and Lingwood CA: Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin. Role of p-glycoprotein in glycolipid synthesis. J Biol Chem 275: 6246-6251, 2000. (Pubitemid 30129914)
41. Gouaze V, Liu YY, Prickett CS, Yu JY, Giuliano AE and Cabot MC: Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 65: 3861-3867, 2005. (Pubitemid 40616367)
42. Veldman RJ, Mita A, Cuvillier O, et al: The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J 17: 1144-1146, 2003.
43. Di Sano F, Di Bartolomeo S, Fazi B, et al: Antisense to glucosylceramide synthase in human neuroepithelioma affects cell growth but not apoptosis. Cell Death Differ 9: 693-695, 2002. (Pubitemid 34618875)
44. Gerrard G, Butters TD, Ganeshaguru K and Mehta AB: Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. Eur J Pharmacol 609: 34-39, 2009.
45. Patwardhan GA, Zhang QJ, Yin D, et al: A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis. PLoS One 4: e6938, 2009.